Product Description: Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation[1][2][3].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Yen CC, et al. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf. 2022 Feb;21(2):157-166./[2]Wang Y, et al. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur J Pharmacol. 2021 Nov 5;910:174500.